Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmaceuticals (Basel)
Egile Nagusiak: Bolcaen, Julie, Nair, Shankari, Driver, Cathryn H. S., Boshomane, Tebatso M. G., Ebenhan, Thomas, Vandevoorde, Charlot
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8308832/
https://ncbi.nlm.nih.gov/pubmed/34209513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14070626
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak